Salt-Tolerant, Protease-Stable and Non-Resistance Developing Cationic AMPs for Combatting Planktonic MRSA and its...

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Antimicrobial resistance is a global health crisis, necessitating novel therapeutics.
• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat, particularly in skin and soft tissue infections.
• MRSA biofilms are highly resistant to conventional antibiotics, and existing antimicrobial peptides (AMPs) face limitations such as cost, stability, and toxicity.

Purpose of the Study:

• To develop novel, potent, and stable antimicrobial peptides (AMPs) as alternatives to conventional antibiotics for targeting MRSA.
• To overcome the limitations of current AMPs, including salt sensitivity, toxicity, and protease degradability.

Main Methods:

• Design and synthesis of two novel membranolytic AMPs: d-WRL (all d-amino acids) and W-(Dab)-L (incorporating 2,4-diaminobutyric acid).
• Evaluation of AMPs' efficacy against planktonic MRSA and MRSA biofilms.
• Assessment of AMPs' stability, toxicity, and potential for resistance development.

Main Results:

• The developed AMPs, d-WRL and W-(Dab)-L, demonstrated high potency against planktonic MRSA and effectively inhibited biofilm formation.
• These AMPs eradicated approximately 80% of mature MRSA biofilms, surpassing vancomycin in killing kinetics and exhibiting protease stability.
• MRSA did not develop resistance to the novel AMPs over 96 generations, unlike ciprofloxacin.

Conclusions:

• The study successfully developed stable, non-toxic, and highly potent AMPs effective against MRSA, including biofilms.
• These novel AMPs represent a significant advancement in combating antimicrobial resistance and offer a promising therapeutic avenue for MRSA infections.
• The developed AMPs overcome key limitations of existing treatments and have the potential to be critical additions to the therapeutic arsenal against MRSA.